NMN / NAD+ Precursors for Alzheimer's Disease
Also known as: Nicotinamide mononucleotide, NR (Nicotinamide Riboside), NAD+ boosters
NAD+ decline with aging contributes to the mitochondrial dysfunction and impaired autophagy central to Alzheimer's pathogenesis.
Mechanism of Action
In Alzheimer's, NAD+ depletion reduces SIRT1 activity (impairing autophagy and amyloid clearance), compromises mitochondrial biogenesis (PGC-1α), and impairs DNA repair (PARP overactivation by amyloid-induced damage). NAD+ restoration addresses multiple converging pathways.
General mechanism: NAD+ precursor. Supports mitochondrial function (Complex I), sirtuin activity (SIRT1/3), DNA repair (PARP), and cellular energy metabolism.
Current Evidence
Preclinical models show NAD+ boosting improves cognition and reduces amyloid pathology. Human trials confirm safety and NAD+ level increases but clinical cognitive endpoints have not been studied in Alzheimer's patients specifically.
Clinical Status: Preclinical for Alzheimer's. Human safety established. Efficacy trials needed.
Safety Profile
Well-tolerated at studied doses (1-2g/day NMN, 500-2000mg/day NR). No significant adverse effects in human trials. Not regulated as pharmaceuticals.
Key Research Questions
- Can NAD+ restoration prevent or slow Alzheimer's in at-risk populations?
- What is the interaction between NAD+ boosting and anti-amyloid therapies?